MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

2019 International Congress

September 22-26, 2019. Nice, France.

View by Title View Sessions
View by Date
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z
  • Body Mass Gain in Parkinson’s Disease Following Deep Brain Stimulation: A Systematic Review

    J. Steinhardt, T. Münte, S. Schmid, B. Wilms, N. Brüggemann (Lübeck, Germany)

  • Body Representation Impairments in Parkinson’s disease: A Preliminary Report

    J. Cardona, C. Martinez, W. Correa, J. Grisales, C. Trujillo, F. Marmolejo-Ramos (Santiago de Cali, Colombia)

  • Botulinum Neurotoxin (BoNT) treatment in functional movement disorders: an extended follow up

    J. Dijk, M. Tijssen, J. Koelman, Y. Dreissen, F. Lambert (Groningen, Netherlands)

  • Botulinum toxin content and activity: Potential implications for duration of efficacy in patients with cervical dystonia

    M. Field, A. Splevins, M. Schans, J. Langenberg, D. Noort, P. Picaut, K. Foster (Rijswijk, Netherlands)

  • Botulinum toxin for the management of dystonic scoliosis in children

    D. Ferman, T. Sanger (Los Angeles, CA, USA)

  • Botulinum toxin injections reduce the symptoms of dystonic tremor and improve sensorimotor function for hand dexterity

    L. Rocchi, A. Latorre, G. Paparella, E. Menozzi, L. Peppoloni, F. Valero-Cuevas, C. Cordivari, K. Bhatia, J. Rothwell (London, United Kingdom)

  • Botulinum toxin treatment of muscle spasms in a case of Satoyoshi syndrome

    I. Bledsoe (San Francisco, CA, USA)

  • Botulinum toxin type A therapy in a movement disorders unit: a 23-year experience.

    M. Velez, C. Cosentino, L. Torres (Lima, Peru)

  • BouNDless: An active-controlled randomized, double-blind double-dummy study of continuous ND0612 infusion in patients with fluctuating Parkinson’s disease

    W. Poewe, K. Kieburtz, F. Stocchi, S. Oren, T. Yardeni, L. Adar, O. Rosenfeld, C. Olanow (Innsbruck, Austria)

  • Braak model in Parkinson disease using MRI biomarkers

    N. Pyatigorskaya, L. Yahia-Cherif, R. Valabregue, R. Gaurav, M. Mongin, C. Ewenczyk, C. Gallea, F. Gargouri, E. Bardinet, I. Arnulf, M. Vidailhet, S. Lehericy (Paris, France)

  • « Previous Page
  • 1
  • …
  • 29
  • 30
  • 31
  • 32
  • 33
  • …
  • 217
  • Next Page »
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • #23660 (not found)
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • Patients with Essential Tremor Live Longer than their Relatives
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley